Lindsey Harris, MD
Retina Specialist · Houston, TXNPI 1093729402
Payments from drug & device makers
What this record shows
28 manufacturers reported payments, led by Novartis at 51.9% of the total. Reporting peaked in 2021 at $4,730 and has fallen 83.4% since, to $784 in 2025.
Across 287 payments — averaging $33.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$5K
- Regeneron Healthcare Solutions, Inc.$1K
- Genentech USA, Inc.$758
- Sun Pharmaceutical Industries Inc.$527
- Bausch & Lomb Americas Inc.$301
- Oyster Point Pharma, Inc.$259
- plus $2K from 22 others
Across 49 payments — averaging $11,892 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$453K
- Apellis Pharmaceuticals, Inc.$103K
- Eyepoint US, Inc.$8K
- AbbVie$7K
- Genentech, Inc.$6K
- Janssen Research & Development, LLC$6K
What the payments were for
- Consulting fees$4,10042%
- Food & beverage$5,63258%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 52 | $5,049 |
| Regeneron Healthcare Solutions, Inc. | 54 | $1,016 |
| Genentech USA, Inc. | 55 | $758 |
| Sun Pharmaceutical Industries Inc. | 32 | $527 |
| Bausch & Lomb Americas Inc. | 10 | $301 |
| Oyster Point Pharma, Inc. | 9 | $259 |
| Tarsus Pharmaceuticals, Inc. | 5 | $238 |
| Apellis Pharmaceuticals, Inc. | 11 | $223 |
| AbbVie(2 entities) | 7 | $220 |
| Astellas Pharma US Inc | 10 | $210 |
| Alcon | 3 | $134 |
| Thea Pharma Inc. | 6 | $111 |
| Alimera Sciences, Inc. | 6 | $106 |
| Harrow Eye, LLC | 4 | $93 |
| Spark Therapeutics, Inc. | 1 | $82 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $78 |
| Kala Pharmaceuticals, Inc. | 4 | $63 |
| Amgen | 3 | $57 |
| Aerie Pharmaceuticals, Inc. | 2 | $45 |
| Carl Zeiss Meditec USA, Inc. | 1 | $27 |
| Shire North American Group Inc | 1 | $23 |
| Eyepoint US, Inc. | 1 | $22 |
| Sight Sciences, Inc. | 1 | $19 |
| Akorn, Inc. | 1 | $17 |
| Eyevance Pharmaceuticals LLC | 1 | $15 |
| Mallinckrodt Enterprises LLC | 1 | $15 |
| GSK | 1 | $15 |
| Travere Therapeutics, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,732 in reported general payments places this provider in the 80th percentile of 108 retina specialist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 139 | $147,977 |
| TyrvayaVarenicline Tartrate | 55 | $64,932 |
| Cyclosporine | 59 | $38,753 |
| XiidraLifitegrast | 27 | $31,824 |
| LumiganBimatoprost | 19 | $10,536 |
| Lotemax SmLoteprednol Etabonate | 37 | $9,021 |
| Travoprost | 65 | $8,487 |
| Prednisolone Acetate | 265 | $7,233 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 47 | $5,931 |
| CombiganBrimonidine Tartrate/Timolol | 17 | $5,759 |
| VyzultaLatanoprostene Bunod | 15 | $5,565 |
| Alphagan PBrimonidine Tartrate | 17 | $5,353 |
| RhopressaNetarsudil Mesylate | 11 | $5,319 |
| Ketorolac Tromethamine | 323 | $5,220 |
| Latanoprost | 563 | $4,949 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $220 | $169,626192 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $259 | $64,93255 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $301 | $37,38942 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm | $78 | $9,02137 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $45 | $5,31911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 108 retina specialist providers in Texas.
Other retina specialist in Houston
- Garvin DavisHouston$38K
- Ella LeungHouston$12K
- Petros CarvounisHouston$8K
- Keith BourgeoisHouston$7K
- Richard FishHouston$5K
- Lee TranHouston$4K
- Michael LamHouston$4K
- John AlappattHouston$4K
- Sapa PhamHouston$4K
- Jie GaoHouston$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.